Compare Repligen Corporation Common Stock (RGEN) vs Trade Desk Inc (TTD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Repligen Corporation Common Stock vs Trade Desk Inc — how do they compare? Repligen Corporation Common Stock trades at $178.15 (market cap $11.14B), while Trade Desk Inc trades at $12.14 (market cap $5.75B). The key difference: Repligen Corporation Common Stock is the larger of the two by market cap, and Repligen Corporation Common Stock is trading nearer its 52-week high, Trade Desk Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Repligen Corporation Common Stock for 0 Days and Trade Desk Inc for 73 Days on average.
| RGEN | TTD | |
|---|---|---|
Market Cap | $11.14B | $5.75B |
Volume | 1,259,263 | 15,249,283 |
Sector | Health | Media |
52-Week High | $194.57 | $54.13 |
52-Week Low | $102.87 | $11.92 |
Typical Hold Time | 0 Days | 73 Days |
Enterprise Value | $11.02B | $4.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RGEN trades at $175.42, up 1.66% today, with a neutral technical signal and key support at $173. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 results due October 27. Revenue grew to $738.26M in 2025, though net income margin is modest at 5.29%. The company recently completed the acquisition of BioLife Solutions, signaling strategic expansion.
Outlook remains positive with strong analyst support (91.67% buy ratings) and a consensus price target of $173.86, though high valuation multiples (P/E 240.34) pose a risk. Earnings growth and integration of acquisitions are key catalysts, but investors face execution risks and market volatility.
The Trade Desk (TTD) trades at $12.18, down 68% year-to-date amid slowing revenue growth and increased competition. Technical indicators show bearish momentum with mixed earnings performance, beating estimates in Q2 but missing in Q1. The company maintains strong profitability margins (76.9% gross margin) but faces headwinds from Amazon and other tech giants expanding into ad-tech. Recent workforce reductions and downward revenue guidance reflect operational challenges.
Despite current pressures, TTD maintains leadership in programmatic advertising with solid cash flow generation. Analyst consensus suggests 20% upside to the $14.68 price target, though competitive threats and slowing growth present significant risks. The stock's valuation appears reasonable with P/E of 0.14 and P/S of 0.02, but investors should weigh the company's ability to defend its market position against larger competitors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Repligen Corporation Common Stock
Repligen Corporation develops and manufactures bioprocessing tools and technologies used in biologic drug manufacturing, including filtration and perfusion systems, chromatography columns and resins, and process analytics instruments. Its products support upstream and downstream production workflows for modalities such as monoclonal antibodies, mRNA, and viral vectors.
Read more on RGEN →About Trade Desk Inc
The Trade Desk Inc is engaged in providing a technology platform for ad buyers. Through its cloud-based platform ad buyers can create, manage, and optimize data-driven digital advertising campaigns across ad formats and channels, including display, video, audio, in-app, native and social, on a multitude of devices. Its products include Data Management Platform, Cross-Device Targeting, Video Advertising, Mobile Advertising, and others.
Read more on TTD →
